Literature DB >> 24060878

Whole-cell screening-based identification of inhibitors against the intraphagosomal survival of Mycobacterium tuberculosis.

Garima Khare1, Praveen Kumar, Anil K Tyagi.   

Abstract

We describe here an efficient strategy that employs whole-cell-based screening and further short listing of the compounds by cytotoxicity- and fluorescence-based intracellular assays, resulting in potential bactericidal hits against the growth of Mycobacterium tuberculosis in broth culture as well as in phagosomes. These compounds also inhibited multidrug-resistant strains of M. tuberculosis but showed no or poor inhibition of nonpathogenic mycobacteria or other bacterial species such as Escherichia coli.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24060878      PMCID: PMC3837871          DOI: 10.1128/AAC.01444-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis.

Authors:  B Yang; H Koga; H Ohno; K Ogawa; M Fukuda; Y Hirakata; S Maesaki; K Tomono; T Tashiro; S Kohno
Journal:  J Antimicrob Chemother       Date:  1998-11       Impact factor: 5.790

2.  Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

Authors:  A H Diacon; P R Donald; A Pym; M Grobusch; R F Patientia; R Mahanyele; N Bantubani; R Narasimooloo; T De Marez; R van Heeswijk; N Lounis; P Meyvisch; K Andries; D F McNeeley
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

3.  Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors.

Authors:  Mudassar Altaf; Christopher H Miller; David S Bellows; Ronan O'Toole
Journal:  Tuberculosis (Edinb)       Date:  2010-10-12       Impact factor: 3.131

4.  Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis.

Authors:  Juan-Carlos Palomino; Anandi Martin; Mirtha Camacho; Humberto Guerra; Jean Swings; Françoise Portaels
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 5.  Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts.

Authors:  Ben J Marais; Knut Lönnroth; Stephen D Lawn; Giovanni Battista Migliori; Peter Mwaba; Philippe Glaziou; Matthew Bates; Ruth Colagiuri; Lynn Zijenah; Soumya Swaminathan; Ziad A Memish; Michel Pletschette; Michael Hoelscher; Ibrahim Abubakar; Rumina Hasan; Afia Zafar; Guiseppe Pantaleo; Gill Craig; Peter Kim; Markus Maeurer; Marco Schito; Alimuddin Zumla
Journal:  Lancet Infect Dis       Date:  2013-03-24       Impact factor: 25.071

6.  Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method.

Authors:  Anandi Martin; Mirtha Camacho; Françoise Portaels; Juan Carlos Palomino
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

7.  Changing patterns and trends of multidrug-resistant tuberculosis at referral centre in Northern India: a 4-year experience.

Authors:  A K Maurya; A K Singh; M Kumar; J Umrao; S Kant; V L Nag; R A S Kushwaha; T N Dhole
Journal:  Indian J Med Microbiol       Date:  2013 Jan-Mar       Impact factor: 0.985

8.  Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening.

Authors:  Sarah A Stanley; Sarah Schmidt Grant; Tomohiko Kawate; Noriaki Iwase; Motohisa Shimizu; Carl Wivagg; Melanie Silvis; Edward Kazyanskaya; John Aquadro; Aaron Golas; Michael Fitzgerald; Huanqin Dai; Lixin Zhang; Deborah T Hung
Journal:  ACS Chem Biol       Date:  2012-05-21       Impact factor: 5.100

9.  Inhibition of mutation and combating the evolution of antibiotic resistance.

Authors:  Ryan T Cirz; Jodie K Chin; David R Andes; Valérie de Crécy-Lagard; William A Craig; Floyd E Romesberg
Journal:  PLoS Biol       Date:  2005-05-10       Impact factor: 8.029

10.  Bedaquiline: First FDA-approved tuberculosis drug in 40 years.

Authors:  Rajiv Mahajan
Journal:  Int J Appl Basic Med Res       Date:  2013-01
View more
  5 in total

1.  System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis.

Authors:  Xingji Zheng; Yossef Av-Gay
Journal:  J Vis Exp       Date:  2017-04-05       Impact factor: 1.355

2.  Unraveling the role of the transcriptional regulator VirS in low pH-induced responses of Mycobacterium tuberculosis and identification of VirS inhibitors.

Authors:  Swati Singh; Nikita Goswami; Anil K Tyagi; Garima Khare
Journal:  J Biol Chem       Date:  2019-05-24       Impact factor: 5.157

3.  Dual Mechanism of Action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis.

Authors:  Saqib Kidwai; Chan-Yong Park; Shradha Mawatwal; Prabhakar Tiwari; Myung Geun Jung; Tannu Priya Gosain; Pradeep Kumar; David Alland; Sandeep Kumar; Avinash Bajaj; Yun-Kyung Hwang; Chang Sik Song; Rohan Dhiman; Ill Young Lee; Ramandeep Singh
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 4.  New insights into TB physiology suggest untapped therapeutic opportunities.

Authors:  Christina E Baer; Eric J Rubin; Christopher M Sassetti
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

5.  Virtual Screening, pharmacophore development and structure based similarity search to identify inhibitors against IdeR, a transcription factor of Mycobacterium tuberculosis.

Authors:  Akshay Rohilla; Garima Khare; Anil K Tyagi
Journal:  Sci Rep       Date:  2017-07-05       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.